MedTrace Logo

A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients

NCT03389815 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2018-01-04

No results posted yet for this study

Summary

The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of WX-0593 alone in the treatment of advanced cancer.

Conditions

  • Advanced Solid Tumor, Non-small Cell Lung Cancer

Interventions

DRUG

WX-0593 Tablets

tablets, dosage ranged from 30 mg to 300 mg, quaque die（QD）

Sponsors & Collaborators

  • Qilu Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yuankai Shi, M.D. · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

  • Jian Fang, M.D. · Peking University Cancer Hospital & Institute

  • Shucai Zhang, M.D. · Beijing Chest Hospital, Capital Medical University

  • Yunpeng Liu, M.D. · First Hospital of China Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-14
Primary Completion
2020-06-30
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03389815 on ClinicalTrials.gov